Chimerix Inc Overview
Pro stress-test →Chimerix Inc was a biopharmaceutical company focused on developing targeted oncology therapies and antivirals. Founded in 2000 and headquartered in Durham, North Carolina, the company underwent a strategic transformation from antiviral development to oncology, with its lead asset dordaviprone in clinical development for H3 K27M-mutant diffuse glioma, a rare pediatric brain tumor with no FDA-approved treatments.
Strategic Profile
Pro stress-test →The company pursued a specialized oncology strategy targeting unmet medical needs in rare, high-grade brain tumors affecting children and young adults. After facing a major clinical setback with its antiviral program in 2015, Chimerix pivoted to leverage its chemical library and expertise in developing the imipridone class of cancer therapies. In March 2025, Jazz Pharmaceuticals announced its acquisition of Chimerix for $935 million, valuing the company's oncology pipeline and near-term revenue potential.
Competitive Landscape
Pro stress-test →Chimerix competed in the rare oncology space against larger pharma companies and specialized biotech firms developing therapies for pediatric brain tumors and other rare cancers. Key competitive categories include immunotherapy platforms, targeted small-molecule therapies, and alternative treatment modalities for gliomas. The acquisition by Jazz Pharmaceuticals positioned the company within a larger portfolio addressing hematologic malignancies and rare diseases.
Industry Context
Chimerix Inc operates in Biopharmaceuticals / Oncology.
Key facts
Founded: 2000 · Headquarters: Durham, NC, US · Employees: 79 · Revenue: $8M (2025 projected) · Market cap: ~$935M (acquisition price)